Production of a specific substrate-human plasminogen--for the quantitative determination of plasminogen activator in the blood plasma in sudden death
Khvatov, V.B.; Petrenko, O.A.
Problemy Gematologii i Perelivaniia Krovi 20(6): 57-60
1975
ISSN/ISBN: 0552-2080 PMID: 1135191 Document Number: 87131
Document emailed within 1 workday
Related Documents
Han, X.M.; Chen, Z.Q.; Mao, H.M. 1990: Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke Zhonghua Nei Ke Za Zhi 29(9): 544-546; 575-576Sprengers, E.D.; Akkerman, J.W.; Jansen, B.G. 1986: Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood Thrombosis and Haemostasis 55(3): 325-329
Yamada, R.; Yamada, S.; Ishii, A.; Tane, S. 1993: Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy Nippon Ganka Gakkai Zasshi 97(8): 955-960
Fujii, S.; Lucore, C.L.; Hopkins, W.E.; Billadello, J.J.; Sobel, B.E. 1990: Induction of synthesis of plasminogen activator inhibitor type-1 by tissue-type plasminogen activator in human hepatic and endothelial cells Thrombosis and Haemostasis 64(3): 412-419
Veremeenko, K.N.; Kizim, A.I. 1974: Determination of plasminogen in human blood plasma Voprosy Meditsinskoi Khimii 20(3): 325-328
Habib, S.S.; Abdel Gader, A.G.M.; Kurdi, M.I.; Suriya, M.O.; Al Aseri, Z. 2012: Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina JPMA. Journal of the Pakistan Medical Association 62(7): 681-685
Glas-Greenwalt, P.; Hall, J.M.; Panke, T.W.; Kant, K.S.; Allen, C.M.; Pollak, V.E. 1986: Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura Journal of Laboratory and Clinical Medicine 108(5): 415-422
De Moerloose, P.; Mermillod, N.; Amiral, J.; Reber, G. 1998: Thrombomodulin levels during normal pregnancy, at delivery and in the postpartum: comparison with tissue-type plasminogen activator and plasminogen activator inhibitor-1 Thrombosis and Haemostasis 79(3): 554-556
Fukao, H.; Yamamoto, K.; Matsuo, O. 1991: Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome Rinsho Byori. Japanese Journal of Clinical Pathology 39(7): 720-726
Shiba, E.; Kobayashi, T.; Yayoi, E.; Takatsuka, Y.; Koyama, H.; Takai, S.; Mori, T. 1992: Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report Nihon Geka Gakkai Zasshi 93(1): 109
Wallnöfer, A.E.; van Griensven, J.M.; Schoemaker, H.C.; Cohen, A.F.; Lambert, W.; Kluft, C.; Meijer, P.; Kooistra, T. 1993: Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans Thrombosis and Haemostasis 70(6): 1005-1008
Virji, M.A.; Aggarwal, S.; Kang, Y. 1989: Alterations in plasminogen activator and plasminogen activator inhibitor levels during liver transplantation Transplantation Proceedings 21(3): 3540-3541
Okamoto, U.; Nagamatsu, Y.; Matsumoto, M.; Yamamoto, J. 1974: Studies on a plasminogen activating system in human milk. I. Isolation of plasminogen activator and proactivator from human milk, and estimation of their molecular weights Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 37(2): 121-131
Kobayashi, Y.; Fukuo, Y.; Shibuya, T.; Terashi, A. 1990: The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 27(5): 578-583
Nelles, L.; Lijnen, H.R.; Van Nuffelen, A.; Demarsin, E.; Collen, D. 1990: Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA) Thrombosis and Haemostasis 64(1): 53-60
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Chandler, W.L.; Schmer, G.; Stratton, J.R. 1989: Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in human plasma Journal of Laboratory and Clinical Medicine 113(3): 362-371
Grøndahl-Hansen, J.; Agerlin, N.; Munkholm-Larsen, P.; Bach, F.; Nielsen, L.S.; Dombernowsky, P.; Danø, K. 1988: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer Journal of Laboratory and Clinical Medicine 111(1): 42-51
Koike, C.; Hayakawa, Y.; Niiya, K.; Sakuragawa, N.; Sasaki, H. 1996: The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1 Thrombosis and Haemostasis 75(2): 298-302
Bernik, M.B.; White, W.F.; Oller, E.P.; Kwaan, H.C. 1974: Immunologic identity of plasminogen activator in human urine, heart, blood vessels, and tissue culture Journal of Laboratory and Clinical Medicine 84(4): 546-558